At the beginning of the two-hour segment, Dr. Kriteman discussed his background at Yale University and his experience working as an investment banker on Wall Street before heading to medical school.
However, for the majority of the interview, Dr. Kriteman explained how the common myth of benign prostatic hyperplasia being connected to prostate cancer is not true. He also examined the minimally invasive and surgical options for the treatment of benign prostatic hyperplasia, including transurethral resection of the prostate (TURP), greenlight, aqua ablation, and Urolift procedures.
Dr. Kriteman closed the segment emphasizing how medication doesn’t have to be the first option of patients suffering from BPH. He stated, “Once I have all of the information on my patient’s case, I can better guide the patient on what their options are. Then, it’s a shared decision between the patient and the surgeon to figure out what’s going to be the best way to achieve the restoration of confidence and health.”
If you missed the show, click here to listen!